Gilead (GILD) calls active into late stage NASH study fails
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Gilead Sciences (GILD) PT Lowered to $87 at Cantor Fitzgerald
February 12, 2019 7:14 AM ESTCantor Fitzgerald analyst Alethia Young lowered the price target on Gilead Sciences (NASDAQ: GILD) to $87.00 (from $92.00) while maintaining a Overweight rating after speaking with management.
STELLAR3 is set to read out in 2Q, and Cantor Fitzgerald has increased caution after the F4... More
Gilead Sciences (GILD) NASH Expectations Were Low, RBC Says; PT Trimmed to $84
February 12, 2019 6:53 AM ESTRBC Capital analyst Brian Abrahams lowered the price target on Gilead Sciences (NASDAQ: GILD) to $84.00 (from $89.00) while maintaining a Outperform rating after the company announced its first ph.III study of selonsertib in NASH, STELLAR 4, failed.
"... we believe expectations were low... More
